Esketamine Nasal Spray for Depression (SUSTAIN-3 Trial)

"Janssen Research & Development, LLC, the primary sponsor for this clinical trial, has announced that the primary outcome being measured over the course of the study is change in heart rate from baseline. This 5 year 3 month long study will also be evaluating secondary outcomes including changes in participant-reported health status, as assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale (VAS), Clinical Global Impression-Severity (CGI-S) score and Participant-Reported Depressive Symptoms Using the Patient Health Questionnaire - 9 (PHQ9) Total Score"

"As of right now, there are 26 Esketamine Nasal Spray clinical trials happening in 95 cities and 31 countries. The first one started back in 2016 and was completed in the Phase 3 drug approval stage. Since then, 48 more studies have been conducted."

"Currently, this trial is not recruiting patients. The study was originally posted on June 9th 2016 and the most recent update was October 12th 2022. However, there are other clinical trials that may be of interest; 1357 studies for patients with depressive disorder and 26 for those specifically interested in Esketamine Nasal Spray."

"Esketamine Nasal Spray is considered safe by our team at Power. This is due to the fact that it is a Phase 3 trial, meaning that there is evidence of its efficacy and multiple rounds of data supporting its safety."

"There are 55 sites running this trial currently, with Boston, Wichita Falls and Ottawa among the locations. To reduce travel requirements, patients should try to enroll at the location nearest them."

"Esketamine Nasal Spray is most frequently used to treat unipolar depression, but it has also been shown to help manage pain, status asthmaticus, and muscle relaxation."

"Esketamine Nasal Spray was first studied in 2016 under the identifier NCT02782104. As of now, there have been 48 completed trials with 26 more presently active and recruiting patients. Most of these latter clinical studies are based out of Boston, Massachusetts."

"This clinical trial is no longer actively recruiting patients, according to the information on clinicaltrials.gov. The study was first posted on June 9, 2016 and was last updated on October 12, 2022. However, there are 1383 other trials currently looking for participants that you may be eligible for."